Abstract
Objective
A randomized-controlled trial comparing study of the changes in brain sensitive-weighted imaging (SWI) of Wilson disease (WD) patients during the treatment with metal chelator was done.
Methods
100 untreated WD patients (80 cases of cerebral type, 20 cases of hepatic type, age 20.13 ± 9.12 years old) and 20 normal controls were selected. Neurological symptoms were scored using the modified Young scale. Liver function tests and copper indices were collected. All study objects received SWI test of the brain. The values of corrected phase (CP) were calculated on SWI. Cerebral-type WD patients were treated with D-penicillamine (DPA) (group 1) or Dimercaptopropane Sulfonate (DMPS) + Dimercaptosuccinic Acid (DMSA) (group 2). Hepatic-type WD patients were treated with DPA (group 3). All patients received annual neurological symptom score, liver function, copper indices, and SWI examination.
Results
At the first year of treatment, score of the modified Young scale in group 2 was lower than that in group 1 (P = 0.023) and lower than that before treatment (P = 0.040). After 2 years of treatment, the score of the modified Young scale in group 1 was lower than that before treatment (P = 0.012). At the second year after treatment, the urinary copper in group 2 was higher than that in group 1 (P = 0.014). Urinary copper was maintained at 200 µg/day in group 1 and 300 µg/day in group 2 after 3 years of treatment. At the first year of treatment, serum copper in group 1 was lower than that in group 2 (P = 0.032). At the first year of treatment, CP values of the pallidum and substantia nigra in group 2 were higher than those in group 1 (P = 0.026, 0.040). At the second year of treatment, CP value of substantia nigra in group 2 was higher than that in group 1 (P = 0.037). After 3 years of treatment, there was no difference in CP values between WD patients and normal controls.
Conclusions
Therapy with DMPS and DMSA improves neurological symptoms of WD patients more quickly and leads to less aggravation, compared with therapy with DPA. The metal content in the brain of WD patients was at a low level after 3 years of treatment. DMPS and DMSA can remove metal from brain tissue faster than DPA.
Similar content being viewed by others
References
Liang X-L (2001) Hereditary diseases of the nervous system. People's Mil Med Publ House 11:46–47
Roberts EA, Schilsky ML (2008) Diagnosis and treatment of Wilson disease: an update. Hepatology 47(6):2089–2111
Wang S, Shi N, Geng Z, Li X, Xin Hu, Wang Z (2014) Inhibitory mechanism of dimercaptopropanesulfonic acid (DMPS) in the cellular biomethylation of arsenic. Biochimie 106:167–174
Yajima Y, Kawaguchi M, Yoshikawa M, Okubo M, Tsukagoshi E, Sato K, Katakura A (2017) The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments. J Pharmacol Sci 134:1–8
Hingwala DR, Kesavadas C, Thomas B, Kapilamoorthy TR (2013) Susceptibility weighted imaging in the evaluation of movement disorders. Clin Radiol 68:338–348
Han Y-H, Lee J-H, Kang B-M, Mun C-W, Baik S-K, Shin Y-i et al (2013) Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy. J Neurol Sci 325:29–35
Zhou X, Li X, Huang W, Liu B, Liang Y, Zhu R et al (2011) (2011) Improved Young scale—a scale for the neural syndrome of Wilson disease. Chin J Nerv Ment Dis 37:171–172
Roberts EA, Schilsky MI (2003) Apractice guideline on Wilson disease. Hepatology 37:1475–1492
Eso Y, Takai A, Takahashi K, Ueda Y, Taura K, Marusawa H, Seno H (2019) Combination of Mac-2 binding protein glycosylation isomer and up-to-seven criteria as a useful predictor for Child–Pugh grade deterioration after transarterial chemoembolization for hepatocellular carcinoma. Cancers (Basel) 11(3):E405
Bergera B, Maderb I, Damjanovicb K, Niesena W-D, Sticha O (2014) Epileptic status immediately after initiation of d-penicillamine therapy in a patient with Wilson’s disease. Clin Neurol Neurosurg 127:122–124
Weiss KH, Stremmel W (2012) Evolving perspectives in Wilson disease: diagnosis, treatment and monitoring. Curr Gastroenterol Rep 14:1–7
Marcellini M, Di Ciommo V, Callea F (2005) Treatment of Wilson’s disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. Lab Clin Med 145:139–143
Pan JJ, Chu CJ, Chang FY (2005) The clinical experience of Chinese patients with Wilson’s disease. Hepatogastroenterology 52(61):166–169
Bruha R, Marecek Z, Pospisilova L et al (2011) Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int 31:83–91
Geetha A, Jeyachristy SA, Selvamathy SM et al (2007) A study on the concentrations of serum zinc, non-ceruloplasmin copper, reactive oxygen and nitrogen species in children with Wilson's disease. Clin Chim Acta 383:165–167
Zhang W, Sun SG, Jiang YH, Qiao X, Sun X, Wu Y (2009) Determination of brain iron contentin patients with Parkinson’s disease using magnetic susceptibility imaging. Neurosci Bull 25(6):353–360
Sorbello O, Sini M, Civolani A, Demelia L (2010) HFE gene mutations and Wilson’s disease in Sardinia. Dig Liver Dis 42:216–219
Rossi M, Ruottinen H, Soimakallio S, Elovaara I, Dastidar P (2013) Clinical MRI for iron detection in Parkinson's disease. Clin Imaging 37:631–636
Mittal S, Wu Z, Neelavalli J, Haacke EM (2009) Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. Am J Neuroradiol 30:232–252
Zhou X-X, Li X-H, Chen D-B, Chao Wu, Feng Li, Qin H-L, Xiao-Yong Pu, Liang X-L (2019) Injury factors and pathological features of toxic milk mice during different disease stages. Brain Behav 00:e01459. https://doi.org/10.1002/brb3.1459
Funding
This study was supported by grants from the Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases (2015B050501003), Guangdong Provincial Engineering Center For Major Neurological Disease Treatment, Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease, Guangdong Provincial Clinical Research Center for Neurological Diseases.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
All authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or research committee and with the 1964 Helsinki declaration and its amendments or comparable ethical standards.
Rights and permissions
About this article
Cite this article
Zhou, X., Xiao, X., Li, Xh. et al. A study of susceptibility-weighted imaging in patients with Wilson disease during the treatment of metal chelator. J Neurol 267, 1643–1650 (2020). https://doi.org/10.1007/s00415-020-09746-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-020-09746-y